A fully integrated protein crystallization platform for small-molecule drug discovery.
Structure-based drug discovery in the pharmaceutical industry benefits from cost-efficient methodologies that quickly assess the feasibility of specific, often refractory, protein targets to form well-diffracting crystals. By tightly coupling construct and purification diversity with nanovolume crystallization, the Structural Biology Group at Syrrx has developed such a platform to support its small-molecule drug-discovery program. During the past 18 months of operation at Syrrx, the Structural Biology Group has executed several million crystallization and imaging trials on over 400 unique drug-discovery targets. Here, key components of the platform, as well as an analysis of some experimental results that allowed for platform optimization, will be described.
Hosfield
David
D
Syrrx, Inc., 10410 Science Center Drive, San Diego, CA 92121, USA.
Palan
John
J
Hilgers
Mark
M
Scheibe
Daniel
D
McRee
Duncan E
DE
Stevens
Raymond C
RC
D003001:Cloning, Molecular; D003460:Crystallization / Q000379:methods*; D015195:Drug Design; D014176:Protein Biosynthesis; D011506:Proteins / Q000737:chemistry* / Q000302:isolation & purification; D012371:Robotics
D011506:Proteins